EPT fúmarat (N-etýl-N-própýltryptamín)

EPT Fumarate (N-ethyl-N-propyltryptamine) – Scientific Product Description

General Features

EPT Fumarate is a research chemical from the tryptamine class, characterized by its unique N-ethyl-N-propyl substitution pattern. This compound exhibits structural similarities to known tryptamines such as DMT and MET, but is distinguished by specific pharmacodynamic properties.

Core specifications:

• Chemical Purity:  >98% (verified by HPLC-MS)

• Molecular Stability:  Excellent stability due to fumarate salt formation

• Leysni:  Freely soluble in water and organic solvents

• Geymsluskilyrði:  Long-term stability at -20°C in inert gas atmosphere

Vísindaleg notkun

1. Neuropharmacological Research:

   • Serotonergic Receptor Interactions (5-HT1A/2A/2C)

   • Monoamine oxidase inhibition studies

   • Neurotransmitter release mechanisms

2. Metabolic Studies:

   • Liver microsome metabolism profile

   • Cytochrome P450 interaction analysis

3. Comparative Pharmacology:

   • Structure-activity relationships versus other N,N-dialkyltryptamines

   • Dose-response characterization in vitro

Experimental Guidelines

Dosage Ranges for In Vitro Studies:

Safety protocols:

• Always work under controlled laboratory conditions

• Personal protective equipment (lab coat, nitrile gloves, safety glasses) required

• Use only in a fume hood when handling solvents

Stöðugleikagögn

Documented Stability:

• Room temperature: <72 hours in solution

• Refrigerated (4°C): stable for 1 week

• Frozen (-20°C): stable for >6 months

Recommended Storage:

• Primary packaging: Amber glass vials with PTFE closure

• Secondary packaging: Vacuum sealed with silica gel pack

• Storage conditions: -20°C under argon atmosphere

Analytical Certification

Each batch comes with:

1. Extensive HPLC analysis (UV/VIS detection)

2. Mass spectrometry confirmation (LC-MS/MS)

3. Residual solvent analysis

4. Water content determination (Karl Fischer)

Legal Status & Ethics

Dutch Regulations:

• Currently not included in the Opium Act

• Valid under general medicinal products legislation for research chemicals

• Mandatory registration for scientific institutions

Siðferðislegar leiðbeiningar:

• For non-clinical research use only

• Prohibited for human or animal administration

• Mandatory ethical review for academic research

Algengar spurningar

Q1: How does EPT compare to structurally similar tryptamines?
A: The ethyl-propyl substitution exhibits unique pharmacokinetic properties, particularly in:

• Lipophilicity profile (logP value: 2.1)

• Protein binding capacity (88-92%)

• Brain barrier penetration (0.65 ratio to DMT)

Q2: What are the detection options in standard drug screenings?
A: EPT is not recognized by conventional immunoassays, but is detectable via:

• GC-MS (characteristic fragmentation at m/z 130, 144)

• LC-QTOF (precision measurement of molecular mass)

Q3: Are there any known interactions with medications?
A: Theoretical interactions are possible with:

• MAO inhibitors (potentiation effect)

• SSRIs (competitive inhibition)

• Antipsychotics (receptor competition)

Q4: What is the recommended waste disposal?
A: Follow the hazardous waste protocol:

• Neutralize with dilute hydrochloric acid (0.1M)

• Absorb with suitable material (e.g. vermiculite)

• Dispose of as hazardous chemical waste (EC number: 404-860-3)

Scientific References

Important literature references:

1. Nichols, D. E. (2018). “Structure-activity relationships of tryptamines”

2. Brandt et al. (2020). “Analytical characterization of novel psychoactive substances”

3. EU Early Warning System (2023). “Risk assessment of new tryptamine derivatives”

This product is intended solely for authorized scientific research by qualified personnel. All information is provided without any implied warranty. Users are responsible for complying with local regulations.